Comprehensive Codified Algorithms to Identify the Underestimated Burden of Hidradenitis Suppurativa in the United States

被引:0
|
作者
Ingram, John R. [1 ]
Geissbuhler, Yvonne [2 ]
Darcy II, John [3 ]
Foley, Stephen [4 ]
Gaffney, Alex [4 ]
McConnon, Aine [4 ]
Richardson, Craig [2 ]
Garg, Amit [5 ]
机构
[1] Cardiff Univ, Dept Dermatol & Acad Wound Healing, Div Infect & Immun, Cardiff, Wales
[2] Novartis Pharm AG, Basel, Switzerland
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Novartis Ireland Ltd, Dublin, Ireland
[5] Northwell Hlth, New Hyde Pk, NY USA
关键词
Hidradenitis suppurativa; HS; Real-world evidence; Algorithm; Diagnosis; Prevalence; Incidence;
D O I
10.1007/s13555-024-01259-0
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
IntroductionHidradenitis suppurativa (HS) is a painful, inflammatory skin disease associated with a high disease burden and long diagnostic delay. Prevalence estimates of HS vary widely in the literature owing to differing estimation methodologies. This study aimed to apply stepwise algorithms to estimate the prevalence of possible/diagnosed cases of HS in the US.MethodsThis was a retrospective cohort study in adult and pediatric patients with HS which utilized data from four US databases (MarketScan [Medicare and Medicaid] and Optum [electronic health record (EHR) and Clinformatics Data Mart (CDM)]). Patients with possible/diagnosed HS were identified using two algorithms (termed Algorithm 1 and Algorithm 2), which assessed symptoms such as multiple skin boils in site-specific areas based on international classification of disease (ICD) codes. Patients with diagnosed HS were defined as having >= 2 outpatient or >= 1 inpatient diagnosis codes of HS. In each database, patients with continuous medical and pharmacy benefits in the 365 days pre-index and 0-365 days post-index periods were eligible for inclusion.ResultsAcross all databases, Algorithm 2 (MarketScan Medicare [N = 309,916]; MarketScan Medicaid [N = 188,783]; Optum EHR [N = 366,158]; Optum CDM [N = 173,812]) identified more patients with possible/diagnosed HS than Algorithm 1 (MarketScan Medicare [N = 194,353]; MarketScan Medicaid [N = 99,276]; Optum EHR [N = 177,957]; Optum CDM [N = 112,244]). Based on ICD-9/10 codes, the 5-year period prevalence of HS ranged from 0.06% to 0.12% across all databases, while for Algorithm 1 and Algorithm 2, this ranged from 0.27% to 0.41% and 0.49% to 0.78%, respectively. Adults and females generally had a higher 5-year period prevalence versus pediatric patients and males, respectively.ConclusionThis real-world study highlights that HS diagnosis codes alone may be insufficient to estimate the prevalence of HS, demonstrating the value of employing algorithms in practice which assess for parameters such as multiple skin boils in site-specific areas. Integrating robust methods to identify the prevalence of HS may improve the diagnostic delay observed in HS and improve treatment outcomes.
引用
收藏
页码:2859 / 2876
页数:18
相关论文
共 50 条
  • [41] Tumour necrosis factor-α inhibitor prescription patterns for hidradenitis suppurativa in the united states veterans affairs healthcare system
    Rypka, Katelyn J.
    Wendland, Zachary
    Herzog, Claire
    Greenlund, Lindsey
    Agiri, Fatai Y.
    Perez, Cristina
    DuVall, Scott L.
    Orenstein, Lauren
    Lynch, Julie A.
    Goldfarb, Noah I.
    EXPERIMENTAL DERMATOLOGY, 2023, 32 : 124 - 125
  • [42] Prevalence Estimates for Hidradenitis Suppurativa among Children and Adolescents in the United States: A Gender- and Age-Adjusted Population Analysis
    Garg, Amit
    Wertenteil, Sara
    Baltz, Rebekah
    Strunk, Andrew
    Finelt, Nika
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2018, 138 (10) : 2152 - 2156
  • [43] Rate of hidradenitis suppurativa readmission has increased in the united states: A 9-year longitudinal study of the national readmission database
    Edigin, E.
    Kaul, S.
    Shaka, H.
    Eseaton, P.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (05) : S67 - S67
  • [44] Rifampin and clindamycin are safe long-term: Response to "North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management"
    Albrecht, Joerg
    Bigby, Michael
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (01) : E31 - E31
  • [45] Hidradenitis suppurativa is associated with increased odds of stroke, coronary artery disease, heart failure, and PAD: A population-based analysis in the United States
    Ward, Rachael A.
    Kakaati, Rayan
    Liu, Beiyu
    Green, Cindy
    Jaleel, Tarannum
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB1 - AB1
  • [46] Gender differences in pain interference with daily activities and functional impairment among patients with hidradenitis suppurativa: A population-based study in the United States
    Kingston, Paige
    Peterson, Hannah
    Lee, Kathryn
    Huang, Margaret Y.
    Yee, Danielle
    Korouri, Edwin
    Armstrong, April W.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025,
  • [47] Assessing trends and burden of occupational exposure to asbestos in the United States: a comprehensive analysis from 1990 to 2019
    Li, Xujun
    Su, Xin
    Wei, Li
    Zhang, Junhang
    Shi, Donglei
    Wang, Zhaojun
    BMC PUBLIC HEALTH, 2024, 24 (01)
  • [48] Impact of the COVID-19 pandemic on assessing incidence and healthcare resource use of myasthenia gravis, Parkinson's disease, and hidradenitis suppurativa patients in the United States
    Lecomte, Coralie
    Dickinson, Harriet
    Raad, Hanaya
    Rudnik, Jan
    Pilipczuk, Olga
    Aguila, Mireia
    Sayed, Sahar
    Bartels, Dorothee B.
    Lamy, Francois Xavier
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 394 - 394
  • [49] Development and validation of coding algorithms to identify patients with incident lung cancer in United States healthcare claims data
    Beyrer, Julie
    Nelson, David R.
    Sheffield, Kristin M.
    Huang, Yu-Jing
    Ellington, Tim
    Hincapie, Ana L.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 (11) : 1465 - 1479
  • [50] Analysis of travel burden and travel support among patients treated at a comprehensive cancer center in the Southeastern United States
    Bai, Jinbing
    Barandouzi, Zahra A.
    Yeager, Katherine A.
    Graetz, Ilana
    Gong, Claire
    Norman, Maria
    Hankins, James
    Paul, Sudeshna
    Torres, Mylin A.
    Bruner, Deborah Watkins
    SUPPORTIVE CARE IN CANCER, 2024, 32 (07)